Clinical Trial Update: Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is investigating neoadjuvant/adjuvant cadonilimab plus chemotherapy in patients with resectable PD-L1 negative non-small cell lung canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cadonilimab

Snippet

Sponsor: Sichuan Cancer Hospital and Research Institute | Conditions: NSCLC | Phase 2 | Status: RECRUITING